53 results found.

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large Clinical Trial using GS-9973

Gilead Sciences - Recruiting 18 years or older.
- A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies.
GS-9973

Hematological Malignancies, Certain Lysosomal Storage and Peroxis Clinical Trial using A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)

Center for International Blood and Marrow Transplant Research - Recruiting N/A or older.
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications.
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)

Hematologic Disease, Hematologic Neoplasm, or Pancytopenia Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Evaluation, Treatment and Training Protocol for Patients With Bone Marrow Failure States, Isolated or Multilineage Cytopenias, Metastatic Solid Tumors, or Hematologic Malignancies.

Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck Clinical Trial using CC-115

Celgene Corporation - Recruiting 18 years or older.
- A Phase 1a/b, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects With Advanced Solid Tumors, and Hematologic Malignancies..
CC-115

Neoplasms Clinical Trial using BI 853520

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Patients With Various Advanced or Metastatic Non-hematologic Malignancies.
BI 853520

Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology, Bon Clinical Trial using Denosumab; Zoledronic acid

Amgen - Recruiting 18 years or older.
- A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometar) in the Treatment of Bone Disease in Subjects With Newly Diagnosed Multiple Myeloma.
Denosumab; Zoledronic acid

Hematologic Malignancies, Disorder Related to Transplantation, or Clinical Trial using Preparative Regimen

St. Jude Children's Research Hospital - Recruiting N/A to 21 years.
- Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen.
Preparative Regimen

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Burkitt Lym Clinical Trial using CPX-351

Children's Hospital Medical Center, Cincinnati - Recruiting 12 Months to 30 years.
- A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults With Recurrent or Refractory Hematologic Malignancies.
CPX-351

Solid Cancers Clinical Trial using MPDL3280A

Genentech - Recruiting 18 years or older.
- A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies.
MPDL3280A

Non-Hodgkin's Lymphoma, Multiple, Mycosis Fungoides, Hodgkin's Ly Clinical Trial using Dasatinib

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years or older.
- Phase I/II Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies..
Dasatinib

Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Myeloid Leukemia, Mul Clinical Trial using Dasatinib; laboratory biomarker analysis

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years or older.
- Phase I/II Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies..
Dasatinib; laboratory biomarker analysis

Solid Tumor, Ovarian Cancer, Non-small Cell Lung Cancer, Chronic Clinical Trial

Cancer Centre of Monoclonal Therapy, LLC - Recruiting 18 years or older.
- Prognostic Potential of Cell Surface Markers and Pim Kinases in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors.

Hematologic Malignancies, or Solid Tumors Clinical Trial using omacetaxine mepesuccinate

Teva Pharmaceutical Industries - Recruiting 18 years or older.
- An Open-Label Study to Investigate the Pharmacokinetics (Absorption, Distribution, Metabolism, and Excretion) of Omacetaxine Mepesuccinate Following Subcutaneous Administration of [14C]Omacetaxine Mepesuccinate in Patients With Relapsed and/or Refractory Hematologic Malignancies or Advanced Solid Tumors.
omacetaxine mepesuccinate

Non Hematologic Cancers, Metastatic Cancer, or Lymphoma Clinical Trial using VS-5584

Verastem, Inc. - Recruiting 18 years or older.
- A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma.
VS-5584

Hematologic Malignancies, or Other Diagnoses, Comorbidities, and Clinical Trial

Fred Hutchinson Cancer Research Center - Recruiting 19 years or older.
- Prospective Assessment of Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life.

Myelodysplastic Syndrome (MDS), Hematologic Neoplasms, Hematologi Clinical Trial using Cord Blood Transplant

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications.
Cord Blood Transplant

Hematologic Disease, Lymphoma, Multiple Myeloma, Myelodysplastic Clinical Trial using Stem cell transplantation

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 80 years.
- Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients With Debilitating Hematologic Diseases.
Stem cell transplantation

Blood Stem Cell Transplant Failure, Leukemia, or Hematologic Mali Clinical Trial using Cyclophosphamide; Fludarabine; Melphalan; Mesna; Rituximab; Stem Cell Transplantation; Thiotepa; Tacrolimus; Mycofenolate mofetil; G-CSF

M.D. Anderson Cancer Center - Recruiting N/A to 75 years.
- Three-arm Clinical Trial for Patients With Hematologic Malignancies and Mismatched Donors - Haploidentical, 1 Antigen Mismatch Related or Unrelated, and Matched Unrelated Donor (MUD)- Using a T-cell Replete Allograft and High-dose Post-transplant Cyclophosphamide.
Cyclophosphamide; Fludarabine; Melphalan; Mesna; Rituximab; Stem Cell Transplantation; Thiotepa; Tacrolimus; Mycofenolate mofetil; G-CSF

Hematopoietic/Lymphoid Cancer Clinical Trial using brentuximab vedotin; laboratory biomarker analysis; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 12 years to 75 years.
- Maintenance Therapy With Brentuximab Vedotin (SGN-35) After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma and CD30+ Hematologic Malignancies.
brentuximab vedotin; laboratory biomarker analysis; pharmacological study

Blood Cancer, or Leukemia Clinical Trial using cyclosporine; Thymoglobulin; mycophenolate mofetil; g-csf

Stanford University - Recruiting N/A to 70 years.
- Allogeneic Hematopoietic Cell Transplantation Using a Non-Myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Older Patients With Hematologic Malignancies.
cyclosporine; Thymoglobulin; mycophenolate mofetil; g-csf

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leu Clinical Trial using ex vivo-expanded cord blood progenitor cell infusion; umbilical cord blood transplantation; double-unit umbilical cord blood transplantation; fludarabine phosphate; cyclophosphamide; total-body irradiation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 6 Months to 45 years.
- Multi-center, Open-label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-The-shelf ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies.
ex vivo-expanded cord blood progenitor cell infusion; umbilical cord blood transplantation; double-unit umbilical cord blood transplantation; fludarabine phosphate; cyclophosphamide; total-body irradiation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis

Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Clinical Trial using clofarabine; cytarabine; busulfan; Plerixafor; cyclophosphamide; antithymocyte globulin (rabbit); stem cells; Tacrolimus; mycophenolate mofetil

St. Jude Children's Research Hospital - Recruiting N/A to 21 years.
- T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant.
clofarabine; cytarabine; busulfan; Plerixafor; cyclophosphamide; antithymocyte globulin (rabbit); stem cells; Tacrolimus; mycophenolate mofetil

Hematologic Malignancies Clinical Trial using Campath 1H; Fludarabine; Stem Cell Transplant; Total Body Irradiation (TBI); FK506 (Tacrolimus) or Cyclosporin

Baylor College of Medicine - Recruiting N/A to 70 years.
- Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Diseases Using Haploidentical Family Donors and Sub-Myeloablative Conditioning With Campath 1H.
Campath 1H; Fludarabine; Stem Cell Transplant; Total Body Irradiation (TBI); FK506 (Tacrolimus) or Cyclosporin

Hematologic Malignancies Clinical Trial using Red blood cell Transfusion

Ottawa Hospital Research Institute - Recruiting 18 years or older.
- Transfusion of Red Cells in Hematopoietic Stem Cell Transplantation: The TRIST Study.
Red blood cell Transfusion

Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplanta Clinical Trial using Melphalan; Fludarabine; Mycophenolate mofetil; Tacrolimus; Cord Blood Infusion; Rituximab; ATG; Busulfan; Clofarabine; Total Body Irradiation (TBI)

M.D. Anderson Cancer Center - Recruiting 1 year to 80 years.
- Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies.
Melphalan; Fludarabine; Mycophenolate mofetil; Tacrolimus; Cord Blood Infusion; Rituximab; ATG; Busulfan; Clofarabine; Total Body Irradiation (TBI)

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymph Clinical Trial using Fludarabine phosphate; Thiotepa; Total body irradiation; Therapeutic allogeneic lymphocytes; Cyclophosphamide; Allogeneic hematopoietic stem cell transplantation (HSCT); Peripheral blood stem cell transplantation; Tacrolimus; Mycophenolate mofetil

Thomas Jefferson University - Recruiting 18 years or older.
- A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies.
Fludarabine phosphate; Thiotepa; Total body irradiation; Therapeutic allogeneic lymphocytes; Cyclophosphamide; Allogeneic hematopoietic stem cell transplantation (HSCT); Peripheral blood stem cell transplantation; Tacrolimus; Mycophenolate mofetil

Hematologic Malignancies Clinical Trial using in vitro expanded Cytokine Induced Killer (CIK) cells

A.O. Ospedale Papa Giovanni XXIII - Recruiting 18 years to 65 years.
- Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK)Cells After Allogeneic Stem Cell Transplantation.
in vitro expanded Cytokine Induced Killer (CIK) cells

Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia, A Clinical Trial using Total Body Irradiation (TBI); Donor Lymphocyte Infusion (DLI); Cyclophosphamide (CY); Tacrolimus; Mycophenolate Mofetil (MMF); Hematopoietic Stem Cell Transplant (HSCT)

Thomas Jefferson University - Recruiting 18 years or older.
- A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using Two Related Donors.
Total Body Irradiation (TBI); Donor Lymphocyte Infusion (DLI); Cyclophosphamide (CY); Tacrolimus; Mycophenolate Mofetil (MMF); Hematopoietic Stem Cell Transplant (HSCT)

Acute Myelogenous Leukemia (AML) in 1st or Subsequent Remission, Clinical Trial using POL6326; Leukapheresis; PBSC Transplant

Polyphor Ltd. - Recruiting 18 years to 75 years.
- A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies.
POL6326; Leukapheresis; PBSC Transplant

Solid Tumor and Hematologic Malignancies Clinical Trial using MEK162

Novartis - Recruiting 18 years or older.
- Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors.
MEK162

GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia Clinical Trial using milatuzumab

Immunomedics, Inc. - Recruiting 18 years or older.
- A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies.
milatuzumab

Leukemia Clinical Trial using allogeneic hematopoietic stem cell transplantation; CliniMACS

Memorial Sloan-Kettering Cancer Center - Recruiting N/A to 75 years.
- Randomized Phase II Trial of Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation.
allogeneic hematopoietic stem cell transplantation; CliniMACS

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodyspla Clinical Trial using EPZ-5676

Epizyme, Inc. - Recruiting 18 years or older.
- A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies.
EPZ-5676

Advanced B-cell Lymphoid Malignancies Clinical Trial using Prednisone; Roflumilast

The University of Texas Health Science Center at San Antonio - Recruiting 18 years or older.
- Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013).
Prednisone; Roflumilast

Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasi Clinical Trial using Chemotherapy and antibodies; Miltenyi Biotec CliniMACS; Allogeneic stem cell transplantation

St. Jude Children's Research Hospital - Recruiting N/A to 24 Months.
- HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies.
Chemotherapy and antibodies; Miltenyi Biotec CliniMACS; Allogeneic stem cell transplantation

Advanced Hematologic Malignancies Clinical Trial using 4SC-202

4SC AG - Recruiting 18 years or older.
- Open Label, Dose Escalation Study of 4SC-202 in Patients With Advanced Hematologic Malignancies: First-In-Man Study of a Newly Developed, Oral Histone Deacetylase Inhibitor.
4SC-202

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leu Clinical Trial using fludarabine phosphate; cyclosporine; sirolimus; mycophenolate mofetil; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; total-body irradiation

Fred Hutchinson Cancer Research Center - Recruiting N/A or older.
- A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-Center Trial.
fludarabine phosphate; cyclosporine; sirolimus; mycophenolate mofetil; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; total-body irradiation

Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Clinical Trial using filgrastim; allogeneic bone marrow transplantation; peripheral blood stem cell transplantation

National Cancer Institute (NCI) - Recruiting 16 years to 65 years.
- A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies.
filgrastim; allogeneic bone marrow transplantation; peripheral blood stem cell transplantation

Hematologic Malignancies Clinical Trial using UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)

A.O. Ospedale Papa Giovanni XXIII - Recruiting 18 years to 70 years.
- UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC) FOR THE TREATMENT OF SEVERE (GRADE III-IV) STEROID-RESISTANT GRAFT VERSUS HOST DISEASE (GvHD): A PHASE I/II TRIAL.
UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)

Acute Myeloid Leukemia, Infantile Leukemia (Both AML and ALL), My Clinical Trial using Sorafenib; Cytarabine; Clofarabine

St. Jude Children's Research Hospital - Recruiting N/A to 31 years.
- A Pilot Pharmacokinetic, Pharmacodynamic and Feasibility Study of Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies.
Sorafenib; Cytarabine; Clofarabine

Solid Tumors, Hematologic Malignancies, or Hepatic Impairment Clinical Trial using Carfilzomib

Onyx Pharmaceuticals - Recruiting 18 years or older.
- An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment.
Carfilzomib

Pharmacokinetics of ASP9853, or Non-hematologic Malignancies Clinical Trial using ASP9853; Docetaxel; Paclitaxel

Astellas Pharma Inc - Recruiting 18 years or older.
- A Phase 1, Multicenter, Open-Label, Dose Escalation Study of ASP9853 in Combination With Either Docetaxel or Paclitaxel in Subjects With Advanced Non-hematologic Malignancies.
ASP9853; Docetaxel; Paclitaxel

Multiple Myeloma, Myelodysplastic Syndrome, Hodgkin's Lymphoma, o Clinical Trial using MK-3475

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects With Hematologic Malignancies.
MK-3475

Multiple Myeloma, or Waldenstrom Macroglobulinemia Clinical Trial using oprozomib

Onyx Pharmaceuticals - Recruiting 18 years or older.
- Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies.
oprozomib

Malignant Neoplasm Clinical Trial using Total-body irradiation; Donor lymphocytes infusion (DLI); Cyclophosphamide; Allogeneic hematopoietic stem cell transplantation (HSCT); Tacrolimus; Mycophenolate mofetil

Thomas Jefferson University - Recruiting 18 years or older.
- A Two Step Approach to Haploidentical Hematopoietic Stem Cell Transplantation for Patients in Remission From HLA Partially-Matched Related Donors-Effect of Maternal Donors on Outcomes.
Total-body irradiation; Donor lymphocytes infusion (DLI); Cyclophosphamide; Allogeneic hematopoietic stem cell transplantation (HSCT); Tacrolimus; Mycophenolate mofetil

Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chr Clinical Trial using total-body irradiation; thiotepa; fludarabine phosphate; allogeneic hematopoietic stem cell transplantation; T cell-depleted hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; tacrolimus; methotrexate; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting N/A to 21 years.
- A Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children.
total-body irradiation; thiotepa; fludarabine phosphate; allogeneic hematopoietic stem cell transplantation; T cell-depleted hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; tacrolimus; methotrexate; laboratory biomarker analysis

Neoplasms, or Hematologic Neoplasms Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Collection of Blood, Bone Marrow, Urine, and/or Tissue Samples From Patients With Solid Tumors, Hematological Malignancies or Non-Malignant Hematologic Disorders or HLA Compatible Family Members.

Hematologic Malignancies Clinical Trial using Chemotherapy followed by Stem Cell Transplantation

Dartmouth-Hitchcock Medical Center - Recruiting 18 years to 75 years.
- Non-Myeloablative Chemotherapy Followed by HLA-Matched Related Allogeneic Stem Cell Transplantation for Hematologic Malignancies.
Chemotherapy followed by Stem Cell Transplantation

Hematologic Malignancy Requiring Allogeneic Stem-cell Transplanta Clinical Trial using Maraviroc 300 mg

Abramson Cancer Center of the University of Pennsylvania - Recruiting 18 years or older.
- A Phase II Study to Assess the Efficacy of Maraviroc, a CCR5-Antagonist in Prophylaxis of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Undergoing Reduced-Intensity Allogeneic Stem-Cell Transplantation From Unrelated Donors.
Maraviroc 300 mg

Hematologic Malignancies Clinical Trial using StemEx

Loyola University - Recruiting 55 years to 73 years.
- An Open Label,Double Arm,Single Center Pilot Study to Evaluate the Safety and Efficacy of Transplantation of Either StemEx, Umbilical Cord Blood Stem and Progenitor Cells Expanded ex Vivo, or an Unmanipulated Cord Blood Unit in the Elderly Population With Hematologic Malignancies Using Reduced Intensity Regimen.
StemEx

Hematologic Neoplasms Clinical Trial using Cyclophosphamide; Hematopoietic Stem Cell Transplantation,

European Institute of Oncology - Recruiting 18 years to 70 years.
- Nonmyeloablative Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies With Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression With Cyclophosphamide Administered Before and After Transplantation..
Cyclophosphamide; Hematopoietic Stem Cell Transplantation,

Transplantation for Hematologic Malignancies Clinical Trial using G-PB Transplant; G-BM Transplant

King Faisal Specialist Hospital & Research Center - Recruiting 16 years to 65 years.
- A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies.
G-PB Transplant; G-BM Transplant

Hematologic Malignancy Clinical Trial using Total Body Irradiation (TBI); Donor Lymphocyte Infusion (DLI); Cyclophosphamide; Stem Cell Infusion

Thomas Jefferson University - Recruiting 18 years or older.
- A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies From One Versus Two HLA Partially-Matched Related Donors.
Total Body Irradiation (TBI); Donor Lymphocyte Infusion (DLI); Cyclophosphamide; Stem Cell Infusion